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Uninsured South Florida vascular surgery patients
are less likely to receive optimal medical
management than their insured counterparts
Dante Yeh, MD, Monique Jones, MS, Carl Schulman, MD, MSPH, Jagajan Karmacharya, MD, FRCS,
and Omaida C. Velazquez, MD, Miami, Fla
Objective: Vascular disease is the most prevalent condition in patients aged>60 years, leading to increasing complications
associated with their comorbid conditions. Poor medical compliance could be one reason why the rate of complications
may be higher in this patient population, particularly the uninsured. This study was conducted to better assess rates of
medication compliance in vascular surgical patients.
Methods: Consecutive patients seen in vascular clinics at a busy tertiary academic center were prospectively studied.
Physicians and physician assistants used a standardized questionnaire to collect patient data and evaluated patients for
coexisting medical conditions and medication use. Optimal medical therapy was defined according to the 2006 American
Heart Association (AHA)/American College of Cardiology (ACC) “Guidelines for Secondary Prevention for Athero-
sclerotic Vascular Disease.” Data were analyzed using multivariate regression.
Results: During the 4-month study period, 180 consecutive patients (47% men) were seen in vascular surgery clinics. Most
patients (79%) were nonsmokers and only 21% admitted to smoking. Comorbid conditions surveyed included hypertension in
141, diabetesmellitus in 56, coronary artery disease in 24, hypercholesterolemia in 89, and chronic renal failure in 13; of these,
61%were insured and 39%had no insurance.Overall, only 31%of all patientswere receiving adequatemedical therapy for their
comorbid conditions, and about 66% were receiving suboptimal medical treatment for their vascular disease. Uninsured
patientswere less likely (19%) than insured patients (39%) to receive optimalmedical therapy (P .012). Lack of insurancewas
a predictor of suboptimal medical therapy for hypertension (odds ratio [OR], 3.13; 95% confidence interval [CI], 1.20-8.16;
P  .016), hypercholesterolemia (OR, 5.1; 95% CI, 1.87-13.88; P  .001), peripheral arterial disease (OR, 13.32; 95% CI,
2.84-62.54, P < .001), and any disease overall (OR, 2.43; 95% CI, 1.21-4.88, P  .012). Overall, men and women were
equally likely (68%) to receive suboptimal medical therapy; however, women were significantly more likely to be undertreated
for coronary artery disease (OR, 0.022; 95% CI, 0.0017-0.293; P < .001).
Conclusions: Compliance with optimal medical therapy for secondary risk factor management amongst our vascular
surgery patients is low. Uninsured patients are less likely to receive optimal medical therapy than their insured
counterparts. This survey provides sobering statistics regardingmedical compliance in our population. This issue deserves
further study and may indirectly affect outcomes in minority groups that are disproportionately represented in our
uninsured patients. ( J Vasc Surg 2010;51:4S-8S.)Coronary artery disease (CAD), peripheral arterial dis-
ease (PAD), and carotid artery stenosis (CAS) are clinical
manifestations of systemic atherosclerotic disease. In the
United States, CAD represents 20% of all deaths1 and
corresponds to $156.4 billion in estimated indirect and
direct costs.2 PAD prevalence increases significantly with
age and is associated with increased mortality rates due to
cardiovascular disease. Even after surgical interventions,
almost half of PAD patients die within a median of 44
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4Smonths’ follow-up, mostly from cardiovascular causes.3 In
fact, a higher mortality rate is prevalent amongst patients with
PAD than patients with angina.4 Furthermore, 30% of isch-
emic strokes are caused by carotid artery atherosclerosis, add-
ing an even higher direct and indirect burden to our health
costs.5 Because of their high association with CAD and car-
diovascular-related death, PAD, abdominal aortic aneurysm
(AAA), and symptomatic CAS are termed CAD equivalents.
There are numerous preventive strategies to reduce the
morbidity and mortality associated with cardiovascular-
related disease. Randomized trials have demonstrated the
efficacy of antiplatelet therapy, 3-hydroxy-3-methylgluatryl
coenzyme A (HMG CoA) reductase inhibitors (statins),
angiotensin-converting enzyme (ACE) inhibitors, and -
blockers in decreasing ischemic events such as stroke and
myocardial infarction and in decreasing overall mortality rates
from vascular death.6-9
Even amodest decrease of blood pressure of 10mmHg
systolic and 5 mm Hg diastolic with any hypertensive
therapy can significantly reduce the incidence of stroke,
CAD, and total cardiovascular mortality.10 The routine
postsurgical use of statins has also been shown to reduce the
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carotid endarterectomy, and peripheral vascular revasculariza-
tions and to decrease the rate of cardiac events.11,12 Statin use
also significantly reduces the incidence of new or worsening
claudication,13 improves walking distance,14 and decreases
the incidence of graft occlusion.15 Better glycemic control in
diabetic patients and smoking cessation in former smokers are
correlated with reduced risk of stroke.16, 17
In an endeavor to decrease morbidity and mortality in
patients at high risk for cardiovascular-related disease, the
American Heart Association (AHA) and the American Col-
lege of Cardiology (ACC) published guidelines for the sec-
ondary prevention ofmyocardial infarction and cardiovascular
death by optimizing medical treatment and risk factor modi-
fication.18 However, under-recognition of PAD and other
noncoronary artery atherosclerotic diseases is associated with
suboptimalmedicalmanagement of cardiovascular disease risk
factors.19
The purpose of this study was to evaluate the rates of
medical compliance with best medical therapy in our own
population of patients. We also tested the hypothesis that
patients without insurance were less likely to receive best
medical therapy compared with their insured counterparts.
METHODS
This study was approved by the Institutional Review
Board of the University of Miami/Miller School of Medi-
cine, which waived the requirement for informed consent.
Patients. A prospective observational study was con-
ducted on all patients seen at vascular surgery clinics affili-
ated with the University of Miami between August 28 and
November 3, 2008. Physicians and physician assistants used
a standardized questionnaire to assess patients during their
preoperative, postoperative, and consultation office visits.
Inquiries were made specific to the reason for the visit.
Comorbid medical conditions were documented, includ-
ing hypertension, diabetes mellitus, CAD, hypercholester-
olemia, and chronic renal insufficiency, as were smoking
status, insurance status, gender, and medication usage by
class, including -blocker, calcium channel blocker, di-
uretic, ACE inhibitor or angiotensin-receptor blocker, an-
tiplatelet agent, and statins. All answers were recorded as
subjectively reported by the patient.
No attempt was made to correlate the responses with
objective measures such as blood pressure measurements,
hemoglobin A1C, total cholesterol panels, or bleeding
times. In addition, we did not distinguish between symp-
tomatic or asymptomatic patients when the visit was for
PAD or CAS. Pain scores, likewise, were not recorded.
Lack of insured status was defined as lacking any form
of insurance, including Medicare or Medicaid. Confirma-
tion of insurance status was performed by query of the
administrative database: CANECare and CERNER.
Definitions. For each comorbid condition, we de-
fined classes of medications that were consistent with opti-
mal medical therapy as defined by the AHA/ACG 2006
“Guidelines for Secondary Prevention for Patients WithCoronary and Other Atherosclerotic Vascular Disease.”20
The following is a summary of our definition of optimal
medical therapy:
● hypertensive patients taking an antihypertensive of any
class;
● diabetic patients (we did not distinguish between type
1 and type 2) taking insulin or an oral hypoglycemic;
● diabetic patients taking an ACE inhibitor unless con-
traindicated;
● patients who reported CAD taking a -blocker and an
antiplatelet agent;
● patients with hypercholesterolemia taking a statin;
● patients with carotid artery stenosis taking an anti-
platelet agent;
● patients with peripheral vascular disease taking an an-
tiplatelet agent, a -blocker, and a statin; and
● patients with chronic kidney disease taking an ACE
inhibitor; and
● tobacco cessation for all.
Statistical analysis. Descriptive statistics were calcu-
lated for all variables. Univariate analysis was performed to
determine the association of insurance status, gender, and
smoking on the receipt of adequate therapy for each co-
morbid condition, including hypertension, diabetes mellitus,
CAD, hypercholesterolemia, chronic renal failure (CRF),
PVD, CAS, and AAA. For variables significant on univariate
analysis, multivariate regression was used to determine inde-
pendent predictors of suboptimalmedical therapy.Results are
reported as odds ratios (OR) with 95% confidence intervals
(CI), and significance was considered at P .05. Data were
analyzed using Stata 10.1 software (StataCorp LP, College
Station, Tex).
RESULTS
Between August 28 and November 3, 2008, 180 pa-
tients were evaluated. Seven did not have completed ques-
tionnaires and were excluded from the statistical analysis.
The remaining 173 patients were included in our study, of
which 82 were men (47%). The mean age of the patients
overall was 62.9 years  13.4. The reasons for clinic visit
included peripheral vascular disease in 82, CAS in 13,
aneurysmal disease (thoracic, abdominal, iliac, mesenteric,
renal) in 34, lower extremity venous disease in 29, and 15
patients with a variety of other vascular conditions, includ-
ing iliac artery stenosis, hemodialysis access, aortic dissec-
tion, thrombosed vein excision, stenosis after a gun shot
wound, brachiocephalic artery stenosis, pseudoaneurysm,
Raynaud disease, and aortic coarctation (Fig 1). There were
37 self-reported smokers (21%). Comorbid conditions sur-
veyed included hypertension in 141, diabetes mellitus 56,
CAD in 24, hypercholesterolemia in 89, and CRF in 13
(Fig 2).
Uninsured patients comprised 39% of the population
and insured patients comprised 61% (Fig 3). Overall, only
31% of patients were receiving adequatemedical therapy for
their comorbid conditions, with nearly two-thirds of pa-
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vascular disease. Uninsured patients were less likely
(19%) than insured patients (39%) to receive optimal
medical therapy (P  .012; Fig 4). Lack of insurance was
a predictor of suboptimal medical therapy for hyperten-
sion (OR, 3.13; 95% CI, 1.20-8.16; P  .016), hyper-
cholesterolemia (OR, 5.1; 95% CI, 1.87-13.88; P 
.001), PAD (OR, 13.32; 95%CI; 2.84-62.54,P .001), and
any disease overall (OR, 2.43; 95% CI, 1.21-4.88, P .012;
Fig 1. The main reasons for office visits were peripheral arterial
disease (PAD), carotid stenosis (CS), aneurysmal disease, and
lower extremity vascular disease.
Fig 2. Comorbid conditions surveyed included hypertension
(HTN), diabetes mellitus (DM), coronary artery disease (CAD),
hypercholesterolemia, and chronic renal failure (CRF).
Fig 3. Almost 40% of patients in the study were uninsured (red
slice).Fig 5). For all comorbid conditions, men and women wereequally likely to receive suboptimal therapy; however,
women were significantly less likely to receive optimal therapy
for CAD (OR, 0.022; 95% CI, 0.0017-0.293; P  .001;
Fig 4. Graph shows percentages of insured and uninsured pa-
tients who received optimal medical therapy.
Fig 5. Graph shows percentages of insured and uninsured patients
receiving suboptimal medical therapy by comorbid condition. CAD,
Coronary artery disease; CRF, chronic renal failure; CS, carotid ste-
nosis; DM, diabetes mellitus; HTN, hypertension; PAD, peripheral
arterial disease. *P .05.
Fig 6. Women were likely to receive suboptimal therapy. Coro-
nary artery disease (CAD).Fig 6).
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The results of our study are consistent with previous
publications on suboptimal medical management.15,21-30
Even in ideal conditions, the success rates in reaching
national targets are dismal. In a study of a socioeconomi-
cally homogeneous, multiethnic, well-educated population
with comprehensive medical benefits, 80% failed to
achieve blood pressure control despite full access to and
active participation in the community’s medical care sys-
tem.31 In addition, physicians seldom increase the dose of
antihypertensive medications or try new treatments in hy-
pertensive patients, despite frequent visits for health care.22
Smoking cessation is associated with a significant de-
crease in stroke risk in only 2 years, and by 5 years after
cessation, stroke risk returns to the level of nonsmokers.17
Strategies proven to double cessation rates include nicotine
replacement therapy32 and antidepressant therapy.32 In
addition, simple strategies such as agreeing to a date on
which the person would stop, discussion of previous diffi-
culties in stopping, and giving the patient a booklet are
effective in improving spontaneous quit rates.33 Despite
these strong data, vascular surgeons have not taken strong
proactive roles in assisting with smoking cessation. A small
retrospective case review found that nicotine replacement
therapy was recommended in5% of current smokers, and
no patients were referred to a smoking cessation class.26
There are many reasons for suboptimal risk factor man-
agement. Some patient factors cited are lack of insurance, lack
of a high school diploma, exposure to violence, lack of a
regular source of care,34minority status, lack of a telephone,35
and financial cost.36 Physician factors include lack of aware-
ness of clinical trial results, delay in translation to clinical
practice, and discrimination (conscious or subconscious).
Optimal medical therapy requires increased attention
and vigilance by the vascular surgeon. Evidence shows
patients are more likely to improve compliance after a
surgical intervention, and vascular surgeons are uniquely
influential in improving medical care.21 At our university,
the monthly cost of a combination of aspirin, lisinopril,
metoprolol, and rosuvastatin is as low as $20. Instituting a
policy of aggressive medical management in all vasculopathic
patients may prove to be cost-effective considering the cost of
a single nonfatalmyocardial infarction or a single nondisabling
stroke. Potential strategies to improve risk factor modification
include an in-hospital educational program,37 community-
wide education,38 offering free medical care,39,40 and the use
of an evidence-based therapy approach.24
Our study has several limitations. First, there is a lack of
statistical power due to small sample size. Even with the
small numbers, however, significant differences became
apparent, and these numbers are likely to remain significant
with a larger population of patients.
Second, despite being a prospective trial, our data were
limited and at times incomplete. We did not distinguish
whether patientswere symptomatic or asymptomatic.We recog-
nize that this is an important factor in patient compliance and
emphasize that future studies should take this into account. Inaddition, demographic factors such as household income, edu-
cational level, and employment status were not recorded. It is
probable that there are additional confounding factors.
Third, and most important, almost the entire data set
was self-reported by patients and is therefore subject to
recall bias. Because of financial and time constraints, we
could not use methods such as pharmacy refills or pill
counts to corroborate patients’ responses. It would have
been extremely helpful if we could have discerned whether
a patient was prescribed a medication and failed to fill it or
was never prescribed the drug in the first place, and whether
a generic alternative was available. No attempt was made to
independently and objectively verify patients’ responses; thus,
we may possibly have over-estimated or under-estimated the
rates of medication usage. However, we concluded that this
approach was justified because patients’ awareness of their
comorbid conditions and a basic understanding of their
medications are probably reflective of their medication
usage. Our sample is reflective of real-world conditions.
Fourth, this study was conducted at a single center.
Although the University of Miami is a tertiary academic
setting, our patient population includes a mixture of white,
Hispanic, and African American, and both insured and
uninsured patients, and is likely representative of the overall
patient population in Miami. However, we recognize that
the conclusions may not be universally applicable.
CONCLUSIONS
At our busy tertiary academic vascular clinics, we found
that only 31% of our patients were receiving optimal medical
therapy for their comorbid conditions. Uninsured patients,
who were disproportionately represented byminority groups,
were less likely to receive optimal medical therapy than their
insured counterparts. Women were less likely to receive opti-
mal medical therapy for CAD. These significant differences
among the female vs male patients need to be further under-
stood and addressed as we strive for optimal management of
patients with vascular disease. This survey provides sobering
statistics regardingmedical compliance in a real-worldmedical
practice. We are currently designing a comprehensive inter-
vention to optimize medical management and hope to imple-
ment it into our practice in an effort to improve cardiovascu-
lar outcomes, improve patient quality of life, and deliver
evidence-based cost-effective care.
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